Navigation Links
Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data
Date:5/9/2011

;

DIFICID™ (fidaxomicin), if approved, will be the first new antibiotic for the treatment of Clostridium difficile infection (CDI) in nearly 30 years. In two Phase 3 trials for the treatment of CDI, fidaxomicin was non-inferior in clinical cure when compared to vancomycin, the only FDA approved product for CDI.  DIFICID also demonstrated superiority to vancomycin in global cure, which is defined as a cure without recurrence, or a sustained cure, through the end of the follow up period. This difference was driven by DIFICID's lower rates of relapse of diarrhea following cessation of the CDI treatment.

About Clostridium difficile Infection (CDI)

Clostridium difficile infection (CDI), commonly referred to as "C. difficile" or "c-diff", has become a significant medical problem in hospitals, long-term care facilities, and in the community and is estimated to afflict more than 700,000 people each year in the U.S.  It is a serious illness resulting from infection of the inner lining of the colon by C. difficile bacteria, which produce toxins that cause inflammation of the colon, severe diarrhea and, in the most serious cases, death.  Patients typically develop CDI from the use of broad-spectrum antibiotics that disrupt normal gastrointestinal (gut) flora, thus allowing C. difficile bacteria to flourish and produce toxins.

Current therapeutic options for CDI include the off-label use of metronidazole and oral vancomycin, the latter being the only FDA-approved treatment.  However, approximately 20% to 30% of CDI patients who initially respond to these treatments experience a clinical recurrence, defined as a relapse or re-establishment of diarrhea, following cessation of the CDI treatment.

Primary risk factors for CDI include broad-spectrum antibiotic use (such as cephalosporins and fluoroquinolones), older age (over 65) and exposure to emerging hyper-virulent strains (BI/
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Rhythmia Medical Highlights Studies to be Presented at Heart Rhythm Society 2011 Annual Scientific Session
2. ConvaTec Supported Studies to be Presented at the 24th Annual Symposium on Advanced Wound Care (SAWC) and Wound Healing Society (WHS)
3. New Study Results Presented on Dexlansoprazole and Lansoprazole Effects on Plavix® (clopidogrel bisulfate)
4. Three Studies Presented at the 2011 SHEA Annual Scientific Meeting Show That the ICU Medical MicroCLAVE® Contributes to a Significant Decrease in Bacterial Transfer and Reduction in Bloodstream Infections
5. REMEDIAL II Results on PLC Systems RenalGuard® to be Presented at ACC 2011s Late Breaking Clinical Trial Session
6. Long-Term Data on QNEXA® to be Presented at The American College of Cardiology Annual Meeting
7. Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2011 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting
8. Advancements in GYN Oncology; Instrumentation and Techniques to be Presented by Nicholas C. Lambrou, M.D. of Miami
9. Urocidin™ Phase III Clinical Trial Results to be Presented at EAU and AUA Conferences
10. New England Patriots Offensive Line Wins Second Annual Madden Most Valuable Protectors Award Presented by Prilosec OTC®
11. New Clinical Study Presented at the American Association of Respiratory Care Finds Masimo Rainbow Acoustic Monitoring Accurate for Respiration Rate Assessment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... -- ResMed Inc. (NYSE: RMD ) today announced results ... the quarter was $453.1 million, a 9 percent increase ... 17 percent increase on a constant currency basis).  Net ... June 30, 2014.  Diluted earnings per share for the ... 30, 2014.  The results for the ...
(Date:7/30/2015)... Calif. , July 30, 2015  EP ... /Alcon executives have recently contacted the Company about ... begin as early as Monday, August 3, 2015.  ... quoted as saying that the coming electronic contact ... of dollars over the next several years.  Novartis ...
(Date:7/30/2015)...  Unichem Pharmaceuticals ( USA ), Inc. ... 25 mg 1000-count bottle to the consumer level. This ... to the identification of a Clopidogrel tablet found in ... risk associated with mistakenly taking a Clopidogrel tablet instead ... experiencing Clopidogrel,s side effects which include bleeding and/or bruising. ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2
(Date:7/31/2015)... ... July 31, 2015 , ... Successful Import/Export Programs:, ... http://www.fdanews.com/importexportprogram , Having FDA-regulated products held at ports costs time, money and ... containment — or even destruction — of products, an FDA insider shows manufacturers ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... recently published a blog post that encourages the understanding and treatment of ankle ... people opt for in-home remedies. This can be dangerous if the condition augments ...
(Date:7/31/2015)... ... July 31, 2015 , ... everMaya ( http://evermaya.com/ ), ... handbag line will be named for Madeline Stuart, an 18-year-old model from Brisbane, ... recognized model with Down syndrome, gracing the front pages of publications across the ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... contributor for LeadingAge’s Center for Aging Services Technologies (CAST) Medication Management Technologies whitepaper. ... and post-acute care providers understand the benefits of using medication management technologies ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Physical therapy for knee osteoarthritis ... patient's quality of life. It keeps the patient from doing what they want or need ... have a hard time using the stairs. The patient's exercise regime may be limited by ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 2Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 4Health News:Absolute PhysioCare & Sports Rehab Promotes Understanding & Treatment of Ankle Sprains 2Health News:everMaya to Launch Madeline Stuart Handbag Line 2Health News:everMaya to Launch Madeline Stuart Handbag Line 3Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 2Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 3
... to be cut to 16 to avoid medical errors , ... Haskell took her 15-year-old son to a teaching university for ... was dead. The cause: failure to rescue, meaning, Haskell said ... upon declines in patients." , He was cared for by ...
... , GAINESVILLE, Fla. , Feb. 4 ... announce today that they have jointly selected Sg2 , a healthcare ... children,s hospital. The assessment began in January with findings projected to be ... at Sg2 will handle this very important assessment, delivering the ...
... , , TORRANCE, Calif. , Feb. ... insurance brokerage and consulting firm in California , has ... management and wellness programs.  Nurtur and Healthyroads are the latest ... important dimension to the company,s extensive employee benefits practice. , ...
... , NEW YORK , Feb. ... Research today announced more than $2.8 million in ... biomarkers of PD. The development of biomarkers is of critical ... development, allowing scientists and clinicians to more accurately identify appropriate ...
... N.J. , Feb 4 Smart Balance, Inc. (Nasdaq: ... on February 25, 2010 , at 9:30 a.m. ET ... 8:30 a.m. ET the same day.  The webcast will be ... call by dialing 1-800-895-0198 from the United States or 1-785-424-1053 ...
... 4, 2010 -- Giving smokers information about their own ... quit smoking, according to a paper published in the ... "Personalized risk assessment has been the mainstay of coronary ... reduction over the last decade," said Dr. Robert Young, ...
Cached Medicine News:Health News:Campaign Calls for Limits on Doctors' Hours 2Health News:Campaign Calls for Limits on Doctors' Hours 3Health News:Sebastian Ferrero Foundation and Shands HealthCare Have Selected Sg2 to Conduct a Needs Assessment for a Gainesville-Based Children's Hospital 2Health News:Sebastian Ferrero Foundation and Shands HealthCare Have Selected Sg2 to Conduct a Needs Assessment for a Gainesville-Based Children's Hospital 3Health News:Keenan Selects Nurtur and Healthyroads for Integrated Disease Management and Personal Wellness Programs 2Health News:Keenan Selects Nurtur and Healthyroads for Integrated Disease Management and Personal Wellness Programs 3Health News:Keenan Selects Nurtur and Healthyroads for Integrated Disease Management and Personal Wellness Programs 4Health News:Michael J. Fox Foundation Awards $2.8 Million to Drive Development of Parkinson's Disease Biomarker Pipeline 2Health News:Michael J. Fox Foundation Awards $2.8 Million to Drive Development of Parkinson's Disease Biomarker Pipeline 3Health News:Michael J. Fox Foundation Awards $2.8 Million to Drive Development of Parkinson's Disease Biomarker Pipeline 4Health News:Smart Balance to Host Webcast/Conference Call on 2009 Fourth-Quarter Results 2Health News:Tests showing smokers their individual risk of future disease will help them quit, says paper 2Health News:Tests showing smokers their individual risk of future disease will help them quit, says paper 3
... 130 has expanded memory capabilities for overnight sleep ... retain oxygen saturation and pulse rate data, and ... suit your needs:, ,1. The Model 130 ... for a single patient, making the device ideally ...
... continuous, or spot check pulse ... and an internal rechargeable battery. ... Study modes make it ideal ... or clinical environment; during emergency ...
... The Autocorr Plus, the fourth ... cost-effective, versatile pulse oximeter/ECG/Respiration Monitor, with ... detect/reject, digital oximetry with SAC (Serial ... high-resolution electroluminescent screen display provides two ...
... Management Program is a Windows based, easy-to-use ... Hand-Held Pulse Oximeter. Using the Smiths ... it rapidly downloads information collected during sleep ... and assists in the Clinician's interpretation by ...
Medicine Products: